Literature DB >> 20228382

Steroid hormone receptor profile of premenopausal endometrial polyps.

Satu Kuokkanen, Lubna Pal.   

Abstract

The etiology and pathogenesis of endometrial polyps (EPs) are only partially understood. To better understand how sex steroids regulate polyp growth, we investigated the messenger RNA (mRNA) expression of the genes of reproductive steroid hormone receptors (estrogen receptors alpha [ERalpha] and beta [ERbeta], G protein-coupled receptor 30 [GPR30], and progesterone receptor [PR]) in EP tissue and autologous normal appearing endometrium (R) Within each patient, the normal appearing endometrial tissue remote from the site of the endometrial polyp (R) was taken as an internal control. Relative expressions of genes of interest within the endometrial polyp were compared to expressions of respective genes within the internal control tissue (i.e. R). R is the abbreviation for normal appearing endometrium in the later calculation formula. Ten patients diagnosed with EP in a tertiary care center were included in this study. Directed biopsies were obtained under hysteroscopy from the EP and from a normal appearing site remote from EP along the opposite uterine wall in each patient. Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) was used for gene expression profiling in the paired tissue samples. The relative gene expression between EP and normal appearing endometrium in each patient was analyzed with 2(-DeltaDeltaCt) method. We found that ERalpha, ERbeta, GPR30, and PR were expressed in both normal appearing endometrium and EP in each patient. ERalpha, ERbeta, GPR30, and PR showed no difference in relative expression in EP samples compared with paired normal endometrial samples from the same uterine cavity. However, the relative expression of PR correlated with that of GPR30 (r = .70, P = .023), suggesting that the co-expression of PR and GPR30 may be a contributory mechanism in the pathogenesis of EPs at least in a subset of women.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228382     DOI: 10.1177/1933719109356803

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  5 in total

1.  Cofilin and slingshot localization in the epithelium of uterine endometrium changes during the menstrual cycle and in endometriosis.

Authors:  Kirsten Morris; Ivanna Ihnatovych; Emily Ionetz; Jennifer Reed; Andrea Braundmeier; Zuzana Strakova
Journal:  Reprod Sci       Date:  2011-06-21       Impact factor: 3.060

2.  Endometrial polyps in women affected by levothyroxine-treated hypothyroidism--histological features, immunohistochemical findings, and possible explanation of etiopathogenic mechanism: a pilot study.

Authors:  Carlo Saccardi; Salvatore Gizzo; Kathrin Ludwig; Maria Guido; Mara Scarton; Michele Gangemi; Raffaele Tinelli; Pietro Salvatore Litta
Journal:  Biomed Res Int       Date:  2013-08-22       Impact factor: 3.411

3.  Endometrial Volume Measured by VOCAL Compared to Office Hysteroscopy for Diagnosis of Endometrial Polyps in Premenopausal Women with Abnormal Uterine Bleeding.

Authors:  Mohamed Laban; Sherif H Hussain; Alaa S Hassanin; Waleed M Khalaf; Mohamed K Etman; Mohammed S E Elsafty; Ahmed M Bahaa Eldin; Ahmad S Hasanien; Noha A Sakna; Mohammed Taema; Mohammed H Mostafa; Marwa M Eisa
Journal:  Obstet Gynecol Int       Date:  2016-11-24

4.  Endometrial polyps in female allograft recipients with abnormal bleedings.

Authors:  Dariusz Rajski; Katarzyna Bobrowska; Bronisława Pietrzak; Mirosław Wielgoś; Paweł Kamiński
Journal:  Prz Menopauzalny       Date:  2014-06-30

5.  Immunohistochemical expression of hormone receptors, Ki-67, endoglin (CD105), claudins 3 and 4, MMP-2 and -9 in endometrial polyps and endometrial cancer type I.

Authors:  Gustavo Filipov Peres; Daniel Spadoto-Dias; Flávia Neves Bueloni-Dias; Nilton José Leite; Leonardo Vieira Elias; Maria Aparecida Custódio Domingues; Carlos Roberto Padovani; Rogério Dias
Journal:  Onco Targets Ther       Date:  2018-07-09       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.